WEST CHESTER, Pa., May 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President & Chief Executive Officer, will present at the upcoming RBC Capital Markets Global Healthcare Conference, which is being held at the InterContinental New York Barclay Hotel from May 16-17, 2023.
Event details:
Date: Wednesday, May 17, 2023
Time: 8:30 am ET
Location: InterContinental New York Barclay Hotel
Participants may access a live webcast of the event through the following link: http://www.veracast.com/webcasts/rbc/healthcare2023/YTj1aT.cfm
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available within 24 hours after conclusion of live event, and the webcast replay expires on August 15, 2023.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered into a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP- 315 (formerly LTX-315 and VP-LTX-315) for dermatologic oncology conditions. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
Terry Kohler
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Kevin Gardner
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Chris Calabrese
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.70 |
| Daily Change: | -0.05 -6.67 |
| Daily Volume: | 382,732 |
| Market Cap: | US$63.390M |
December 20, 2024 November 20, 2024 November 04, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
